MX2014005798A - Apoaequorina para reducir daño neuronal debido a isquemia. - Google Patents

Apoaequorina para reducir daño neuronal debido a isquemia.

Info

Publication number
MX2014005798A
MX2014005798A MX2014005798A MX2014005798A MX2014005798A MX 2014005798 A MX2014005798 A MX 2014005798A MX 2014005798 A MX2014005798 A MX 2014005798A MX 2014005798 A MX2014005798 A MX 2014005798A MX 2014005798 A MX2014005798 A MX 2014005798A
Authority
MX
Mexico
Prior art keywords
apoaequorin
injury due
neuronal injury
ischemia
neurons
Prior art date
Application number
MX2014005798A
Other languages
English (en)
Other versions
MX350259B (es
Inventor
Mark Y Underwood
James R Moyer
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of MX2014005798A publication Critical patent/MX2014005798A/es
Publication of MX350259B publication Critical patent/MX350259B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona composiciones a base de apoaequorina y métodos para preacondicionamiento de neuronas en un sujeto para reducir daño neuronal debido a isquemia cerebral. Los métodos incluyen la etapa de administrar apoaequorina a neuronas en un sujeto, en donde el apoaequorina inicia un cambio en niveles de expresión de citosina resultando en una reducción de daño neuronal debido a isquemia cerebral como se compara con neuronas no administradas con apoaequorina. Se describen varias formulaciones, incluyendo dosis inyectables.
MX2014005798A 2011-11-15 2012-11-15 Apoaequorina para reducir daño neuronal debido a isquemia. MX350259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
PCT/US2012/065291 WO2013074798A1 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Publications (2)

Publication Number Publication Date
MX2014005798A true MX2014005798A (es) 2014-05-30
MX350259B MX350259B (es) 2017-08-31

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005798A MX350259B (es) 2011-11-15 2012-11-15 Apoaequorina para reducir daño neuronal debido a isquemia.

Country Status (24)

Country Link
US (1) US20140294874A1 (es)
EP (1) EP2780027B1 (es)
JP (1) JP6181061B2 (es)
KR (1) KR102009932B1 (es)
CN (1) CN104244966B (es)
AU (1) AU2012340446B2 (es)
BR (1) BR112014011630A2 (es)
CA (1) CA2855719C (es)
CY (1) CY1119300T1 (es)
DK (1) DK2780027T3 (es)
ES (1) ES2643392T3 (es)
HK (1) HK1202417A1 (es)
HR (1) HRP20171532T1 (es)
HU (1) HUE035017T2 (es)
IL (1) IL232494B (es)
IN (1) IN2014CN04009A (es)
LT (1) LT2780027T (es)
MX (1) MX350259B (es)
PL (1) PL2780027T3 (es)
PT (1) PT2780027T (es)
SG (1) SG11201402364WA (es)
SI (1) SI2780027T1 (es)
WO (1) WO2013074798A1 (es)
ZA (1) ZA201403577B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
EP3515212A1 (en) * 2016-09-23 2019-07-31 Quincy Bioscience LLC Apoaequorin and vitamin d-containing compositions and methods of using same
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
CN102137681B (zh) * 2008-08-08 2014-12-03 埃姆诺医药有限公司 抗胰腺癌抗体
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Also Published As

Publication number Publication date
HK1202417A1 (en) 2015-10-02
PT2780027T (pt) 2017-10-04
CA2855719C (en) 2021-10-26
SI2780027T1 (sl) 2017-11-30
ES2643392T3 (es) 2017-11-22
JP2014533692A (ja) 2014-12-15
SG11201402364WA (en) 2014-09-26
CA2855719A1 (en) 2013-05-23
DK2780027T3 (en) 2017-09-25
IL232494A0 (en) 2014-06-30
JP6181061B2 (ja) 2017-08-16
ZA201403577B (en) 2015-07-29
HUE035017T2 (en) 2018-03-28
NZ624736A (en) 2016-05-27
EP2780027A1 (en) 2014-09-24
IL232494B (en) 2019-03-31
MX350259B (es) 2017-08-31
LT2780027T (lt) 2017-10-25
IN2014CN04009A (es) 2015-10-23
CY1119300T1 (el) 2018-02-14
EP2780027B1 (en) 2017-07-19
KR102009932B1 (ko) 2019-08-12
WO2013074798A1 (en) 2013-05-23
PL2780027T3 (pl) 2017-11-30
BR112014011630A2 (pt) 2017-06-27
HRP20171532T1 (hr) 2017-11-17
AU2012340446B2 (en) 2017-08-31
KR20140097369A (ko) 2014-08-06
CN104244966B (zh) 2019-01-11
US20140294874A1 (en) 2014-10-02
CN104244966A (zh) 2014-12-24
AU2012340446A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
IN2014DN09434A (es)
MX2021001982A (es) Administracion local y concomitante de nanoportadores sinteticos, tolerogenicos para reducir la hipersensibilidad tipo i y tipo iv.
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
MY166014A (en) Combination therapy methods for treating proliferative diseases
MX2019009437A (es) Tratamiento de mielosupresion.
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ631144A (en) Compositions and methods for transmucosal absorption
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX348708B (es) Métodos para mejorar el desarrollo del cerebro y la función cognoscitiva al usar beta-hidroxi-beta-metilbutirato.
MX2015004362A (es) Derivados de ketamina.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2014005798A (es) Apoaequorina para reducir daño neuronal debido a isquemia.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
MX2015011588A (es) Tratamiento de combinacion.
MX2015007280A (es) Terapia de combinacion para cancer.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
WO2012158776A3 (en) Combination therapy for treatment of cancer
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis

Legal Events

Date Code Title Description
FG Grant or registration